Last updated 19 days ago
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
300 patients around the world
Available in Argentina, United States
Novo Nordisk A/S
2Research sites
300Patients around the world
This study is for people with
Obesity
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Informed consent obtained before any study-related activities.Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.Female or male.Age 18 years or above at the time of signing the informed consent.History of at least one self-reported unsuccessful dietary effort to lose body weight.Body mass index (BMI) greater than or equal to 30.0 kilogram per square meter (kg/m^2), or BMI greater than or equal to 27.0 kg/m^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
- History of type 1 or type 2 diabetes.Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.Previous dosing of marketed or non-marketed amylin-based compounds.
Sites
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
CEDIC Centro de Investigación Clínica - CABA, Buenos Aires
StudyRENEW 1
SponsorNovo Nordisk A/S
Study typeInterventional
Conditions
Obesity
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07220642
